Lentivirus vector in gene therapy of β-thalassemia

doi:10.16352/j.issn.1001-6325.2023.12.1876

Abstract

Abstract: β-thalassemia is a common monogenic inherited blood disorder caused by mutations of β-globin gene which results to synthesis obstacles or abnormal structure of β-globin. Gene therapy mediated by lentiviral vector(LVV) is divided into gene-integration strategies using LVV to add fully functional β-hemoglobin(HBB) genes to chromosomes and gene-editing strategies using LVV to deliver specific ribozymes to hematopoietic stem cells for in situ repair of HBB genes. Improving viral titration and transduction efficiency, reducing target loss and advancing clinical trials are the main targets of these two strategies.

Key words: lentivirus vector, gene therapy, β-thalassemia

CLC Number:

R459.9

LIU Yize, CHAN Ying, ZHU Baosheng. Lentivirus vector in gene therapy of β-thalassemia[J]. Basic & Clinical Medicine, 2023, 43(12): 1876-1880.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.12.1876

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I12/1876

References 25

[1]	Yu FH, Huang KJ, Wang CT. HIV-1 mutant assembly, processing and infectivity expresses pol independent of gag[J]. Viruses, 2020, 12:54-59.
[2]	Lee S, Cobrinik D. Improved third-generation lentiviral packaging with pLKO.1C vectors[J]. Biotechniques 2020, 68:349-352.
[3]	Yudovich D, Backstrom A, Schmiderer L, et al. Comb-ined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells[J]. Sci. Rep, 2020, 10:22393.doi: 10.1038/s41598-020-79724-x.
[4]	Nualkaew T, Sii-Felice K, Giorgi M, et al. Coordinated β-globin expression and α2-globin reduction in a multiplex lentiviral[J]. Mol Ther, 29:2841-2853.
[5]	于榛, 仝帅, 白玥, 等. 优化第三代慢病毒载体稳定表达β-珠蛋白治疗β-地中海贫血的研究[J]. 中国实验血液学杂志, 2022, 30:844-850.
[6]	Lamsfus-Calle A, Daniel-Moreno A, Urena-Bailen G, et al. Hematopoietic stem cell gene therapy: the optimal use of lentivirus and gene editing approaches[J]. Blood Rev, 2020, 40:100641.doi: 10.1016/j.blre.2019.100641. Epub 2019 Nov 15.
[7]	Morgan RA, Unti MJ, Aleshe B, et al. Improved titer and gene transfer by lentiviral vectors using novel, small beta-globin locus control region elements[J]. Mol Ther, 2020, 28:328-340.
[8]	Ouyang WJ, Dong GY, Zhao WH, et al. Restoration of beta-globin expression with optimally designed lentiviral vector for beta-thalassemia treatment in chinese patients[J]. Hum Gene Ther, 2021, 32:481-494.
[9]	Schott JW, Leon-Rico D, Ferreira CB, et al. Enhancing lentiviral and alpharetroviral transduction of human hematopoietic stem cells for clinical application[J]. Mol Ther Methods Clin Dev, 2019, 14:134-147.
[10]	Ozog S, Timberlake ND, Hermann K, et al. Resveratrol trimer enhances gene delivery to hematopoietic stem cells by reducing antiviral restriction at endosomes[J]. Blood, 2019, 134:1298-1311.
[11]	Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibeglogene autotemcel gene therapy for non-beta(0)/beta(0) genotype beta-thalassemia[J]. N Engl J Med, 386:415-427.
[12]	Magrin E, Semeraro M, Hebert N, et al. Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial[J]. Nat Med, 2022, 28:81-88.
[13]	Hongeng S, Anurathapan U, Songdej D, et al. Wild-type HIV infection after treatment with lentiviral gene therapy for beta-thalassemia[J]. Blood Adv, 2021, 5:2701-2706.
[14]	Tucci F, Galimberti S, Naldini L, et al. A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders[J]. Nat Commun, 2022, 13:1315.doi: 10.1038/s41467-022-28762-2.
[15]	Cosenza LC, Zuccato C, Zurlo M, et al. Co-treatment of erythroid cells from beta-thalassemia patients with CRISPR-Cas9-based beta(0)39-globin gene editing and induction of fetal hemoglobin[J]. Genes, 2022, 13:1727.doi: 10.3390/genes13101727.
[16]	Ling S, Yang S, Hu X, et al. Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA [J]. Nat Biomed Eng, 2021, 5:144-156.
[17]	Ortinski PI, O′donovan B, Dong X, et al. Integrase-deficient lentiviral vector as an all-in-one platform for highly efficient CRISPR/Cas9-mediated gene editing[J]. Mol Ther Methods Clin Dev, 2017, 5:153-164.
[18]	Li QY, Gao YM, Wang HF. CRISPR-based tools for fighting rare diseases[J]. Life-Basel, 2022, 12:1968.doi: 10.3390/life12121968.
[19]	Kwon J, Kim M, Hwang W, et al. Extru-seq: a method for predicting genome-wide Cas9 off-target sites with[J]. Genome Biol, 2023, 24:4.doi: 10.1186/s13059-022-02842-4.
[20]	Apolonia L. The old and the new: prospects for non-Integrating lentiviral vector technology[J]. Viruses-Basel, 2020, 12:1016.doi: 10.3390/v12101103.
[21]	Gee P, Lung MSY, Okuzaki Y, et al. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping[J]. Nat Commun, 2020, 11:1334.doi: 10.1038/s41467-020-14957-y.
[22]	Mangeot PE, Risson V, Fusil F, et al. Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins[J]. Nat Commun, 2019, 10:45.doi: 10.1038/s41467-018-07845-z.
[23]	Indikova I, Indik S. Highly efficient ‘hit-and-run’ genome editing with unconcentrated lentivectors carrying Vpr.Prot.Cas9 protein produced from RRE-containing transcripts[J]. Nucleic Acids Res, 2020, 48:8178-8187.
[24]	Uchida N, Ferrara F, Drysdale CM, et al. Sustained fetal hemoglobin induction in vivo is achieved by BCL11A interference and coexpressed truncated erythropoietin receptor[J]. Sci Transl Med, 2021, 13:eabb0411.doi: 10.1126/scitranslmed.abb0411.
[25]	Liu BY, Brendel C, Vinjamur DS, et al. Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat ll-hemoglobinopathies br[J]. Mol Ther, 2022, 30:2693-2708.